Literature DB >> 10857966

Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study.

F de Vegt1, J M Dekker, C D Stehouwer, G Nijpels, L M Bouter, R J Heine.   

Abstract

OBJECTIVE: To compare the risks of all-cause and cardiovascular disease (CVD) mortality in the American Diabetes Association (ADA) and World Health Organization (WHO) glucose tolerance categories after 9 years of follow-up in the Hoorn Study and to study the test-retest reproducibility of those categories. RESEARCH DESIGN AND METHODS: In this population-based cohort study of 2,468 elderly men and women, subjects were classified according to both the WHO and the ADA criteria. Causes of death were extracted from the medical records. Age- and sex-adjusted relative risks were estimated by Cox's proportional hazards model. Reproducibility of the diagnostic criteria was assessed in a sample of 1,109 subjects with duplicate oral glucose tolerance tests.
RESULTS: Subjects with known diabetes had a four to five times higher risk of all-cause and CVD mortality compared with normal subjects (P<0.05). The relative risks of all-cause mortality were 1.67 (95% CI 1.09-2.57) and 1.56 (1.00-2.43) for newly diagnosed diabetic subjects according to the WHO and ADA criteria, respectively. The WHO and ADA criteria had similar levels of reproducibility The overall K was 0.59 (0.54-0.64) for WHO criteria and 0.61 (0.56-0.66) for ADA criteria. For the category of newly diagnosed diabetes according to WHO or ADA, the percentages of agreement for the second test compared with the first test were 77% (85/110) and 74% (74/100), respectively.
CONCLUSIONS: Both sets of diagnostic criteria identify criteria-specific diabetic subjects with an increased mortality risk compared with normal subjects, and the reproducibility of both criteria is similar.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10857966     DOI: 10.2337/diacare.23.1.40

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart.

Authors:  M Bartnik; L Rydén; K Malmberg; J Ohrvik; K Pyörälä; E Standl; R Ferrari; M Simoons; J Soler-Soler
Journal:  Heart       Date:  2006-08-11       Impact factor: 5.994

2.  [Impaired glucose metabolism in patients with ischaemic heart disease].

Authors:  M Leschke; B Schwenk; C Bollinger; M Faehling
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

3.  Lifetime risk and projected population prevalence of diabetes.

Authors:  D J Magliano; J E Shaw; S M Shortreed; W J Nusselder; D Liew; E L M Barr; P Z Zimmet; A Peeters
Journal:  Diabetologia       Date:  2008-09-23       Impact factor: 10.122

4.  A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism--The Hoorn Study.

Authors:  G Bos; J M Dekker; G Nijpels; F de Vegt; M Diamant; C D A Stehouwer; L M Bouter; R J Heine
Journal:  Diabetologia       Date:  2003-06-18       Impact factor: 10.122

Review 5.  The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diagnostic test accuracy.

Authors:  Yicong Ye; Hongzhi Xie; Xiliang Zhao; Shuyang Zhang
Journal:  Cardiovasc Diabetol       Date:  2012-12-27       Impact factor: 9.951

6.  Predictive Power for Type 2 Diabetes Mellitus using Dynamic Change of Metabolic Syndrome, Dynamic Change of Fasting Plasma Glucose, Metabolic Syndrome and Fasting Plasma Glucose.

Authors:  Hui Zhou; Chen Yang; Chen Dong; Zhirong Guo; Xiaoshu Hu; Yong Xu; Zhengyuan Zhou
Journal:  Iran J Public Health       Date:  2014-04       Impact factor: 1.429

7.  Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes.

Authors:  Jang Won Son; Dong Jun Kim; Chang Beom Lee; Seungjoon Oh; Kee-Ho Song; Chan Hee Jung; Ji Oh Mok; Jong Hwa Kim; Min Kyong Moon; Kyung Mook Choi; Jae Hyoung Cho; Sung Hee Choi; Soo Kyung Kim; Kang Seo Park; Hye Soon Kim; In Joo Kim; Young Il Kim; Hae Jin Kim; Sang Yong Kim; Sungrae Kim
Journal:  J Diabetes Investig       Date:  2013-03-26       Impact factor: 4.232

8.  Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants.

Authors: 
Journal:  Lancet Diabetes Endocrinol       Date:  2015-06-21       Impact factor: 32.069

9.  Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study.

Authors:  Esther van 't Riet; Marjan Alssema; Josina M Rijkelijkhuizen; Piet J Kostense; Giel Nijpels; Jacqueline M Dekker
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.